Harvard Bioscience Price Target Raised to $4.00 for 2023
March 25, 2023
Trending News 🌥️
Harvard Bioscience ($NASDAQ:HBIO) has seen a surge in their stock prices recently, with analysts predicting a price target of $4.00 by 2023. Harvard Bioscience is a leading provider of tools and technologies that enable life science research, drug discovery, and clinical diagnostics. With a keen focus on innovative product development, they are a well-respected player in the sector. Their comprehensive portfolio of instruments, consumables, and services supports researchers and clinicians who are advancing medical research and clinical practice. The raise in price target for Harvard Bioscience reflects the confidence that investors have in the company’s future growth prospects.
As their product portfolio continues to expand, their revenue opportunities will grow as well. Moreover, their strong customer base and proven track record of success should help to ensure the company’s success in the coming years. With a strong product portfolio and proven track record, Harvard Bioscience is poised to take advantage of the industry’s current period of growth.
Market Price
On Friday, HARVARD BIOSCIENCE stock opened at $2.8 and closed at $3.0, representing a 7.9% increase from the previous closing price of $2.8. This caused Cowen & Co to raise their price target for HARVARD BIOSCIENCE for 2023 to $4.00. The raised price target reflects increased investor confidence in the company’s potential and indicates that the stock is expected to rise significantly over the next few years. With this new price target, HARVARD BIOSCIENCE is well-positioned to capitalize on future growth opportunities and capitalize on its potential. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Harvard Bioscience. More…
| Total Revenues | Net Income | Net Margin |
| 113.33 | -9.52 | -8.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Harvard Bioscience. More…
| Operations | Investing | Financing |
| 1.15 | -1.59 | -2.84 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Harvard Bioscience. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 145.36 | 73.14 | 1.72 |
Key Ratios Snapshot
Some of the financial key ratios for Harvard Bioscience are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -0.8% | 28.0% | -5.9% |
| FCF Margin | ROE | ROA |
| -0.4% | -5.7% | -2.9% |
Analysis
GoodWhale has conducted an analysis of HARVARD BIOSCIENCE‘s fundamentals and our Star Chart shows that they are classified as an ‘elephant’ company, meaning they are rich in assets after deducting off liabilities. This makes them an attractive target for value investors, such as those looking for companies with a low price to earnings ratio and high dividend yields. HARVARD BIOSCIENCE appears to have strong fundamentals in terms of asset strength, medium profitability and weak growth, with a health score of 6/10 considering its cashflows and debt. This suggests that the company is positioned to safely ride out any crisis without the risk of bankruptcy. More…
Peers
Harvard Bioscience Inc. is a leading manufacturer and distributor of scientific instruments, systems, and supplies. Its competitors are Tecan Group AG, Stevanato Group SPA, and Bio-Techne Corp.
– Tecan Group AG ($OTCPK:TCHBF)
Tecan Group AG is a Switzerland-based company that develops, manufactures and markets laboratory instruments and solutions for the biopharmaceutical, forensics and clinical diagnostics markets. It offers products and services under three divisions: Lab Instrumentation, Lab Automation and Lab Services. The Lab Instrumentation division focuses on the development and manufacture of laboratory instruments, including microplate readers, washers and shakers, and liquid handling products. The Lab Automation division provides laboratory automation solutions, including robotics and software, for use in drug discovery and other life science research applications. The Lab Services division offers a range of services, including reagent and consumable rental, instruments maintenance and technical support.
– Stevanato Group SPA ($NYSE:STVN)
The Stevanato Group is a leading provider of integrated solutions for the pharmaceutical and biotech industries. The Group offers a complete range of products and services, from primary packaging to finished product delivery, to support the development and commercialization of new therapies. The Group has a strong track record of innovation and a commitment to customer service and quality. The Stevanato Group operates in more than 30 countries and employs over 5,000 people.
– Bio-Techne Corp ($NASDAQ:TECH)
Bio-Techne Corp is a global biotechnology company that develops, manufactures, and sells protein-based products, including antibodies, enzymes, and other proteins. The company has a market cap of 11.87B as of 2022 and a Return on Equity of 11.44%. Bio-Techne’s products are used in research and development by the life science industry, as well as in diagnostics and therapeutics by the healthcare industry. The company’s products are sold in over 90 countries worldwide.
Summary
Harvard Bioscience is a global developer, manufacturer, and marketer of a broad range of specialized products, mainly used for life science research and drug discovery. Recently, the company’s price target for 2023 was raised to $4.00. This positive development led to the stock price increasing the same day. Going forward, investors may want to conduct further research into Harvard Bioscience to determine if it is a good investment opportunity. Analysts should consider the company’s financials, including sales and earnings performance, trends in the industry, competitive landscape, and management strength.
Additionally, they should also review macroeconomic factors and assess the potential risks associated with the investment.
Related Posts
Recent Posts
